All News
Filter News
Found 806,074 articles
-
STAAR Surgical Opens EVO Experience Center in United States
11/17/2022
STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, announced the opening of the first company-operated EVO Experience Center.
-
IntegriChain Partners with PurpleLab to Enhance Pharmaceutical Channel Data for More Accurate GTN Forecasting and Accruals
11/17/2022
IntegriChain announced a strategic data partnership with PurpleLab, a healthcare technology company delivering analytics to drive real-world evidence decision-making.
-
JDRF Celebrates Tzield™ (teplizumab-mzwv) Approval
11/17/2022
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S Food and Drug Administration to approve Provention Bio's Tzield™ (teplizumab-mzwv).
-
BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report
11/17/2022
BioLife Solutions, Inc. today announced that it has been selected for inclusion in the BioSpace Best Places to Work in Biopharma 2023 Report.
-
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
11/17/2022
Takeda today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared to imatinib.
-
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
11/17/2022
Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing.
-
Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality
11/17/2022
Element Materials Technology (Element), a leading global Testing, Inspection and Certification (TIC) company, today unveiled one of the first and largest post-pandemic, commercial bioaerosol testing facilities.
-
Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
11/17/2022
Universal Diagnostics today announced the results of a study evaluating putative methylation markers in biological context of early colorectal cancer (CRC) development.
-
Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)
11/17/2022
Kinevant Sciences today announced that the first patient has been dosed in its RESOLVE-Lung study.
-
GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection
11/17/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced findings from a fundamental substudy of the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study, demonstrating that methylation had the most promising combination of cancer detection and prediction of cancer signal origin when compared with other evaluated approaches.
-
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
11/17/2022
Evaxion Biotech A/S today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.
-
Millstone Medical Outsourcing Completes Acquisition of MycoScience
11/17/2022
Millstone Medical Outsourcing, the industry's leading partner of choice for medical manufacturers' post-manufacturing and aftermarket services, announces its completed acquisition of MycoScience, on November 14, 2022.
-
Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus
11/17/2022
Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the initiation of a Phase 2 clinical study of EP547 in subjects with cholestatic pruritus.
-
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
11/17/2022
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
-
Varian Announces First Participant Treated in GENESIS II Clinical Trial of Genicular Artery Embolization for Knee Osteoarthritis
11/17/2022
Varian, a Siemens Healthineers company, announced today that the first trial participant has been treated as part of GENESIS II (Genicular artEry embolisatioN in patiEnts with oSteoarthrItiS of the knee), a study of Embozene® microspheres for genicular artery embolization (GAE) as treatment of mild to moderate knee osteoarthritis.
-
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
11/17/2022
Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.
-
Calyx Medical Imaging Advances Neuro-oncology Treatment Development through AI
11/17/2022
Calyx today announced a strategic partnership with Neosoma, Inc.
-
FDA Warns Seven Companies for Selling Dietary Supplements with Claims to Treat Cardiovascular Disease
11/17/2022
Today, the U.S. Food and Drug Administration issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate or prevent cardiovascular disease or related conditions, such as atherosclerosis, stroke or heart failure, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
-
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
11/17/2022
ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.
-
NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS
11/17/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell ™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail.